Peptide Therapeutics for Osteoarthritis: Osteoimmune Mechanisms, Clinical Evidence, and Priorities for Translation
Journal of Functional Morphology and Kinesiology · 2026-11-09 · 11 (4) · 469
DOI: 10.3390/jfmk11040469 ↗At a glance
Journal article in Journal of Functional Morphology and Kinesiology, published online on 2026-11-09. Written by Sümeyye Akçay and 8 co-authors. 53 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Osteoarthritis is a heterogeneous whole-joint disorder involving mechanical dysfunction, inflammatory signaling, extracellular matrix degradation, and abnormal subchondral bone remodeling. This narrative review evaluates peptide therapeutics by biological function and translational readiness. We synthesize evidence on immunomodulatory and pro-resolution peptides, growth-factor-derived and mimetic peptides, exploratory soft-tissue repair peptides, extracellular matrix-derived and biomimetic peptides, dietary peptide hydrolysates, and peptide-based delivery systems. Evidence from human osteoarthritis, experimental osteoarthritis, focal osteochondral defects, and broader inflammatory or tissue-repair settings is distinguished. Selected peptides show anti-inflammatory, anti-catabolic, or reparative effects in cell and animal models, but these findings do not establish clinical efficacy. Human studies predominantly examine oral collagen hydrolysates and report formulation-specific improvements in pain or function. Their interpretation is limited by small samples, analysis populations, short follow-up, and reporting quality. Investigational intra-articular peptides provide additional signals, although negative primary endpoints and exploratory structural analyses require caution. No peptide intervention reviewed has established reproducible structural disease modification in human osteoarthritis. Clinical translation requires independently replicated efficacy, adequate safety assessment, reproducible manufacturing, and prospective trials that distinguish symptomatic improvement from structural disease modification.
Cite
APA
Akçay, S., Yavaş, A. D., Cipolloni, V., Centioni, G., Bellomo, M. G., Saggini, R., Bonifacio, M., Musorrofiti, M. G., & Conforti, A. (2026). Peptide Therapeutics for Osteoarthritis: Osteoimmune Mechanisms, Clinical Evidence, and Priorities for Translation. Journal of Functional Morphology and Kinesiology, 11(4), 469. https://doi.org/10.3390/jfmk11040469
Vancouver
Akçay S, Yavaş AD, Cipolloni V, Centioni G, Bellomo MG, Saggini R, et al. Peptide Therapeutics for Osteoarthritis: Osteoimmune Mechanisms, Clinical Evidence, and Priorities for Translation. Journal of Functional Morphology and Kinesiology. 2026;11(4):469. doi:10.3390/jfmk11040469
BibTeX
@article{Akay2026,
author = {Akçay, Sümeyye and Yavaş, Arzu Dinç and Cipolloni, Valerio and Centioni, Giulia and Bellomo, Maria Grazia and Saggini, Raoul and Bonifacio, Marco and Musorrofiti, Marco Giuseppe and Conforti, Alessandro},
title = {Peptide Therapeutics for Osteoarthritis: Osteoimmune Mechanisms, Clinical Evidence, and Priorities for Translation},
journal = {Journal of Functional Morphology and Kinesiology},
year = {2026},
volume = {11},
number = {4},
pages = {469},
doi = {10.3390/jfmk11040469}
}
EUVIMED